Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene 
Welcome,         Profile    Billing    Logout  
 85 Diseases   4 Trials   4 Trials   181 News 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
JX594-REN026, NCT03294083: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting
1b/2a
89
US, RoW
Pexastimogene Devacirepvec (Pexa-Vec), JX-594, Cemiplimab
SillaJen, Inc., Regeneron Pharmaceuticals
Renal Cell Carcinoma
08/23
11/23
2016-000085-32: The purpose of this study is to evaluate the safety and efficacy of the combination of two products Pexa-Vec and nivolumab for the treatment of liver cancer L'obiettivo dello studio clinico è di valutare la sicurezza e l'efficacia della combinazione dei due prodotti Pexa-Vec e nivolumab per il trattamento del tumore del fegato

Not yet recruiting
1/2
55
Europe
pexastimogene devacirepvec, nivolumab, [Pexa-Vec], [nivolumab], Suspension for injection, Concentrate for solution for infusion, OPDIVO - 10 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 4 ML- 1 FLACONCINO
TRANSGENE SA, TRANSGENE
Hepatocellular carcinoma Carcinoma epatocellulare, Liver cancer Tumore del fegato, Diseases [C] - Cancer [C04]
 
 
NCT04849260: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Recruiting
1/2
54
RoW
Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy
Lee's Pharmaceutical Limited
Local Progression or Metastatic Melanoma With Failed First-line Treatment
05/22
05/23
METROmaJX, NCT02630368: A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma

Checkmark Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Sep 2018 - Sep 2018: Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Recruiting
1/2
197
Europe
Cyclophosphamide and JX-594 dose escalation, Brand name : ENDOXAN, Brand name: Pexa-Vec, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide, Brand name: ENDOXAN, Brand name: Avelumab
Institut Bergonié, National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene
Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
05/23
11/24

Download Options